Literature DB >> 31434708

EBV Latency III-Transformed B Cells Are Inducers of Conventional and Unconventional Regulatory T Cells in a PD-L1-Dependent Manner.

Héloïse Auclair1, Catherine Ouk-Martin1, Lilian Roland1, Pauline Santa1, Hazar Al Mohamad1, Nathalie Faumont1, Jean Feuillard1,2, Chantal Jayat-Vignoles3.   

Abstract

EBV infects and immortalizes B cells in vitro and in vivo. It is the causative agent of most immune deficiency-related lymphoproliferative disorders and is associated with various lymphomas. EBV latency III-transformed B cells are known to express two immunosuppressive molecules, IL-10 and PD-L1, two characteristics of regulatory B cells (Bregs). In this study, we show that, in addition to secretion of the Breg immunosuppressive cytokines IL-10, IL-35, and TGF-β1, EBV latency III-transformed B cells were able to repress proliferation of their autologous T cells preactivated by CD2, CD3, and CD28. This inhibitory effect was likely caused by CD4+ T cells because EBV latency III-transformed B cells induced a strong proliferation of isolated autologous CD8 T cells. Indeed, EBV was able to promote expansion of autologous FOXP3+ CD39high CTLA4+, Helios+, GITR+, LAG3+ CD4 T cells (i.e., regulatory T cells [Tregs]). Two types of Tregs were induced: unconventional CD25neg and conventional CD25pos Tregs. These Tregs expressed both the latency-associated peptide (LAP) and the PD-1 receptor, two markers of functional Tregs. Expansion of both Treg subtypes depended on PD-L1, whose expression was under the control of LMP1, the main EBV oncogene. These results demonstrate that, like Bregs, EBV latency III-transformed B cells exhibit strong immunoregulatory properties. These data provide clues to the understanding of how after EBV primo-infection, EBV-proliferating B cells can survive in an aggressive immunological environment and later emerge to give rise to EBV-associated B cell lymphomas such as in elderly patients.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31434708      PMCID: PMC6731452          DOI: 10.4049/jimmunol.1801420

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

Review 1.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.

Authors:  Christophe Le Clorennec; Ibtissam Youlyouz-Marfak; Eric Adriaenssens; Jean Coll; Georg W Bornkamm; Jean Feuillard
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

3.  Regulatory role of mature B cells in a murine model of inflammatory bowel disease.

Authors:  E Mizoguchi; A Mizoguchi; F I Preffer; A K Bhan
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

Review 4.  Epstein-Barr virus associated lymphoproliferations in the AIDS setting.

Authors:  R F Ambinder
Journal:  Eur J Cancer       Date:  2001-07       Impact factor: 9.162

5.  Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

Authors:  A H Sarris; K O Kliche; P Pethambaram; A Preti; S Tucker; C Jackow; O Messina; W Pugh; F B Hagemeister; P McLaughlin; M A Rodriguez; J Romaguera; H Fritsche; T Witzig; M Duvic; M Andreeff; F Cabanillas
Journal:  Ann Oncol       Date:  1999-04       Impact factor: 32.976

Review 6.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

7.  A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.

Authors:  Eric Adriaenssens; Alexandra Mougel; Gautier Goormachtigh; Estelle Loing; Véronique Fafeur; Claude Auriault; Jean Coll
Journal:  Oncogene       Date:  2004-04-08       Impact factor: 9.867

8.  Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.

Authors:  Christophe Le Clorennec; Tan-Sothéa Ouk; Ibtissam Youlyouz-Marfak; Stéphanie Panteix; Catherine-Claude Martin; Julia Rastelli; Eric Adriaenssens; Ursula Zimber-Strobl; Jean Coll; Jean Feuillard; Chantal Jayat-Vignoles
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

9.  Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.

Authors:  Giovanna Borsellino; Markus Kleinewietfeld; Diletta Di Mitri; Alexander Sternjak; Adamo Diamantini; Raffaella Giometto; Sabine Höpner; Diego Centonze; Giorgio Bernardi; Maria Luisa Dell'Acqua; Paolo Maria Rossini; Luca Battistini; Olaf Rötzschke; Kirsten Falk
Journal:  Blood       Date:  2007-04-20       Impact factor: 22.113

10.  Stringent doxycycline-dependent control of gene activities using an episomal one-vector system.

Authors:  Georg W Bornkamm; Christian Berens; Conny Kuklik-Roos; Jean-Marie Bechet; Gerhard Laux; Jürgen Bachl; Martin Korndoerfer; Martin Schlee; Michael Hölzel; Anastassia Malamoussi; Rob D Chapman; Falk Nimmerjahn; Josef Mautner; Wolfgang Hillen; Hermann Bujard; Jean Feuillard
Journal:  Nucleic Acids Res       Date:  2005-09-07       Impact factor: 16.971

View more
  4 in total

1.  PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations.

Authors:  Valery Volk; Sebastian J Theobald; Simon Danisch; Sahamoddin Khailaie; Maja Kalbarczyk; Andreas Schneider; Julia Bialek-Waldmann; Nicole Krönke; Yun Deng; Britta Eiz-Vesper; Anna Christina Dragon; Constantin von Kaisenberg; Stefan Lienenklaus; Andre Bleich; James Keck; Michael Meyer-Hermann; Frank Klawonn; Wolfgang Hammerschmidt; Henri-Jacques Delecluse; Christian Münz; Friedrich Feuerhake; Renata Stripecke
Journal:  Front Oncol       Date:  2021-01-12       Impact factor: 6.244

2.  PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival.

Authors:  Oscar Jimenez; Tamara Mangiaterra; Sandra Colli; Mercedes García Lombardi; Maria Victoria Preciado; Elena De Matteo; Paola Chabay
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

Review 3.  B cell-T cell interplay in immune regulation: A focus on follicular regulatory T and regulatory B cell functions.

Authors:  Diaoyi Tan; Wei Yin; Fei Guan; Wanjiang Zeng; Pamela Lee; Fabio Candotti; Louisa K James; Niels Olsen Saraiva Camara; S M Mansour Haeryfar; Yan Chen; Kamel Benlagha; Lewis Zhichang Shi; Jiahui Lei; Quan Gong; Zheng Liu; Chaohong Liu
Journal:  Front Cell Dev Biol       Date:  2022-09-23

Review 4.  Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma.

Authors:  Paola Chabay
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.